Class Cert. Denied In Pfizer Pay-For-Delay Suit

Law360, Los Angeles (January 30, 2014, 10:18 PM ET) -- A Tennessee federal judge on Thursday refused to grant class certifications to two groups claiming Pfizer Inc.’s King Pharmaceuticals Inc. settled a patent dispute with a deal to keep muscle relaxant Skelaxin off the market in a pay-for-delay arrangement that kept the drug prices at brand-name levels.

U.S. District Judge Curtis L. Collier shut down the bids of a group of end payors and a group of indirect purchasers who argued they, as classes, were wronged by the drugmakers in the patent dispute because the deal...
To view the full article, register now.